4Choi YS, Billings JA. 0pioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation [J]. J Pain Symptom Manag, 2002, 24( 1 ) :71-90.
5Hoskin PJ, Hanks GW. Opioid agonist-antagonist drags in acute and chronic pain states[J]. Drugs, 1991, 41(3) :326-344.
6Smith K, Hopp M, Mundin G, et al. Low absolute bioavailabili- ty of oral naloxone in healthy subjects[ J]. Int J Clin Pharmacol Ther, 2012, 50(5):360-367.
7Lahmeyer HW, Craig RJ. Pentazocine-naloxone: another " ad-diction-proof" drug of abuse[J], lnt J Addict, 1987, 22( 11 ) : 1163-I 166.
8John W, John G. Analgesic compositions: US, 4582835 [ P]. 1986-04-15.
9Orman JS, Keating GM. Buprenorphine/naloxone : a review of its use in the treatment of opioid dependence[J] . Drugs, 2009, 69 (5) :577-607.
10Soyka M. Buprenorphine and buprenorphine/naloxone soluble- film for treatment of opioid dependence [ J ]. Expert Opin Drug Deliv, 2012, 9(11):1409-1417.
